According to The Insight Partners new research study on “Fill Finish Manufacturing Market to 2027 – Global Analysis and Forecast – by Product and End User,” The growth of the market is attributed to rising adoption of prefilled syringes for parenteral administration, and elevating demand for biologics. However, the growing competition in biopharmaceutical contract manufacturing industry hinders the growth of the market.
Fill-finish is the final manufacturing step (and perhaps the most critical) in the overall drug manufacturing process. It comes after upstream bioprocessing and also takes place after downstream purification. Fill finish manufacturing involves aseptically filling of biological drugs or medicines in any form, such as sterile liquid, powder, and suspension, in vials, ampoules, bottles syringes, and cartridges.
Get sample Research Copy on Fill Finish Manufacturing Market at: https://www.theinsightpartners.com/sample/TIPRE00018228/
|Market Size Value in||(US$ 6,129.03 million in 2019)|
|Market Size Value by||(US$ 12,547.23 million by 2027)|
|Growth Rate||(CAGR of 9.6% from 2020 to 2027)|
|No. of Pages||(172)|
|Segments covered||(By Product, End User and Geography)|
|Regional scope||(North America; Europe; Asia Pacific; Latin America; MEA)|
|Country scope||(US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina)|
|Report coverage||(Revenue forecast, company ranking, competitive landscape, growth factors, and trends)|
The scope of the fill finish manufacturing market includes the product, end user and region. The market for fill finish manufacturing is analyzed based on regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the fill finish manufacturing market emphasizing on various parameters such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the globe.
Rising Adoption of Prefilled Syringes for Parenteral Administration and Elevated Demand for Biologics
Parenteral administration is one of the most prominent routes chosen to stimulate immediate immune response and ensure 100% bioavailability of pharmaceutical products. A steady rise in the development and market availability of parenteral drugs has propelled the demand for advanced, cost-effective drug delivery devices that promise ease of administration. The prefilled syringes segment is witnessing a significant growth in the fill-finish manufacturing market. The benefits of prefilled syringes over traditional delivery systems include easy administration, improved safety, accurate dosing, and reduced contamination risks. Among drug delivery devices, prefilled syringes represent one of the fastest-growing primary packaging formats, which are also designed for dose administration. In the past 10 years, there has been an evident increase in the development of parenteral drugs (especially with the introduction of several classes of biologics), which has resulted in approximately three-fold increase in the consumption of prefilled syringes.
Biologics constitute a majority of the top-selling drugs, and they presently represent one of the fastest-growing pharmaceutical industry segments. Since the launch of recombinant protein-based therapies, ~30 years back, the overall biologics market has grown at an annual rate of more than 12%. Fill finish is the final step in the production process, and it is one of the most crucial stages of drug manufacturing. Biologics require special procedures and equipment for fill finish operations to ensure product integrity and safety. Thus, the rise in demand for biologics has resulted in an equivalent need for flexible aseptic fill finish technologies.
COVID-19 pandemic has become the most significant challenge across the world. However, the pandemic has brought several growth opportunities to the pharmaceutical and biopharmaceutical companies to strengthen their R&D for vaccine formulation against the coronavirus. Moderna, Inc. and Catalent, Inc. announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington.
Download the Latest COVID-19 Analysis on Fill Finish Manufacturing Market Growth Research Report at: https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00018228
The fill finish manufacturing market, based on end user, is segmented into contract manufacturing organizations, biopharmaceutical companies, and other end users. The contract manufacturing organizations segment held the largest share of the market in 2019 and is anticipated to register the highest CAGR of 10.1% in the market during the forecast period.
The fill finish manufacturing market, based on product, is segmented into consumables and instruments. The consumables segment is further segmented into prefilled syringes, vials, cartridges, and other consumables. In 2019, the consumables segment accounted for a larger share of the market and is expected to register a higher CAGR during the forecast period. Growth of this segment is attributed to high replacement rate compared with that of the instruments segment, rising adoption of prefilled syringes, wide applications of vials in lyophilization, and increasing fill-finish outsourcing.
Fill Finish Manufacturing Market: Competitive Landscape and Key Developments
Becton, Dickson and Company, West Pharmaceutical Services, Gerresheimer AG, Robert Bosch GmbH, IMA Industria Macchine Automatiche S.p.A., OPTIMA, Bausch+Strobel, Groninger and Co. GmbH, Maquinaria Industrial Dara, NIPRO MEDICAL CORPORATION, SCHOTT AG, SGD Pharma, and Stevanato Group are among the key companies operating in the global fill finish manufacturing market. Leading players are focusing on the expansion and diversification of their market presence, and acquisition of new customer base, thus tapping prevailing business opportunities.
In December 2020, BD invested US$ 1.2 billion in its pre-fillable syringe manufacturing capacity to fund capacity expansion, new product innovations, and manufacturing technology enhancements. As a result, the company’s new manufacturing facility in Europe is expected to be operational by the end of 2023.
In February 2019, West Pharmaceutical and Scission AG entered into a partnership for the development of integrated solution for clinical filling of SmartDose drug delivery platform cartridges. Swissfillon AG is a provider of aseptic fill and finish services; through this partnership, it is expected to offer fill-finish capabilities to customers using West’s SmartDose drug delivery platform for complex molecules.
Order a Copy of Fill Finish Manufacturing Market Shares, Strategies and Forecasts 2021-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00018228/
Browse Related Reports and get Sample copy
Central Fill Pharmacy Automation System Market Forecast to 2028 – Covid-19 Impact and Global Analysis – by Product and Service (Equipment, Software, Services); Vendors (Equipment Vendors, Consulting Vendors) and Geography
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
More Research: https://www.biospace.com/article/fill-finish-manufacturing-market-rising-adoption-of-prefilled-syringes-for-parenteral-administration-and-elevated-demand-for-biologics/
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email: Send Email